|
2022 Journal Article Vaginal vault smear cytology in detection of recurrence after hysterectomy for early cervical cancerGrace, Leah, Sanday, Karen, Garrett, Andrea, Land, Russell, Nicklin, Jim, Obermair, Andreas, Rao, Archana, Tang, Amy and Allanson, Emma R. (2022). Vaginal vault smear cytology in detection of recurrence after hysterectomy for early cervical cancer. International Journal of Gynecological Cancer, 32 (7) ijgc-2021-003302, 853-860. doi: 10.1136/ijgc-2021-003302 |
|
2022 Journal Article Toward incorporating health-related quality of life as coprimary end points in clinical trials: time to achieve clinical important differences and QoL profilesGebski, Val, Obermair, Andreas and Janda, Monika (2022). Toward incorporating health-related quality of life as coprimary end points in clinical trials: time to achieve clinical important differences and QoL profiles. Journal of Clinical Oncology, 307 (21) e2102750, 2378-2388. doi: 10.1200/jco.21.02750 |
|
2022 Journal Article Germline BRCA variants, lifestyle and ovarian cancer survivalGersekowski, Kate, Delahunty, Rachel, Alsop, Kathryn, Goode, Ellen L., Cunningham, Julie M., Winham, Stacey J., Pharoah, Paul, Song, Honglin, Jordan, Susan, Fereday, Sian, DeFazio, Anna, Friedlander, Michael, Obermair, Andreas and Webb, Penelope M. (2022). Germline BRCA variants, lifestyle and ovarian cancer survival. Gynecologic Oncology, 165 (3), 437-445. doi: 10.1016/j.ygyno.2022.03.020 |
|
2022 Journal Article Are endometrial cancer clinical practice management guidelines sufficiently consumer centric?Obermair, Andreas, McNally, Orla, Farrell, Rhonda, Ribeiro, Reitan and Ng, Joseph Soon-Yau (2022). Are endometrial cancer clinical practice management guidelines sufficiently consumer centric?. International Journal of Gynecologic Cancer, 32 (7), ijgc-2022. doi: 10.1136/ijgc-2022-003580 |
|
2022 Journal Article Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancerCohen, Paul A., Webb, Penelope M., King, Madeleine, Obermair, Andreas, Gebski, Val, Butow, Phyllis, Morton, Rachael, Lawson, Wanda, Yates, Patsy, Campbell, Rachel, Meniawy, Tarek, McMullen, Michelle, Dean, Andrew, Goh, Jeffrey, McNally, Orla, Mileshkin, Linda, Beale, Philip, Beach, Rhonda, Hill, Jane, Dixon, Cyril, Hegarty, Sue, Codde, Jim, Ives, Angela, Lee, Yeh Chen, Brand, Alison, Mellon, Anne, Bilic, Sanela, Black, Isobel, Jeffares, Stephanie and Friedlander, Michael (2022). Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer. International Journal of Gynecological Cancer, 32 (4) 002999, 560-565. doi: 10.1136/ijgc-2021-002999 |
|
2022 Journal Article Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: a qualitative studyO'Hara, Montana, Janda, Monika, McCarthy, Alexandra L., Nicklin, James, Walker, Graeme and Obermair, Andreas (2022). Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: a qualitative study. Gynecologic Oncology Reports, 39 100914, 100914. doi: 10.1016/j.gore.2021.100914 |
|
2022 Journal Article Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns)Beesley, Vanessa L., Ross, Tanya L., King, Madeleine T., Campbell, Rachel, Nagle, Christina M., Obermair, Andreas, Grant, Peter, DeFazio, Anna, Webb, Penelope M. and Friedlander, Michael L. (2022). Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns). Gynecologic Oncology, 164 (2), 437-445. doi: 10.1016/j.ygyno.2021.12.006 |
|
2022 Journal Article Post-recurrence survival in patients with cervical cancerCibula, David, Dostálek, Lukáš, Jarkovsky, Jiri, Mom, Constantijne H., Lopez, Aldo, Falconer, Henrik, Scambia, Giovanni, Ayhan, Ali, Kim, Sarah H., Isla Ortiz, David, Klat, Jaroslav, Obermair, Andreas, Di Martino, Giampaolo, Pareja, Rene, Manchanda, Ranjit, Kosťun, Jan, dos Reis, Ricardo, Meydanli, Mehmet Mutlu, Odetto, Diego, Laky, Rene, Zapardiel, Ignacio, Weinberger, Vit, Benešová, Klára, Borčinová, Martina, Cardenas, Fernando, Wallin, Emelie, Pedone Anchora, Luigi, Akilli, Huseyin, Abu-Rustum, Nadeem R. ... van Lonkhuijzen, Luc R.C.W. (2022). Post-recurrence survival in patients with cervical cancer. Gynecologic Oncology, 164 (2), 362-369. doi: 10.1016/j.ygyno.2021.12.018 |
|
2021 Journal Article Fertility-sparing management of early-stage endometrial cancer in reproductive age women: current treatment outcomes and future directionsJanda, Monika and Obermair, Andreas (2021). Fertility-sparing management of early-stage endometrial cancer in reproductive age women: current treatment outcomes and future directions. International Journal of Gynecological Cancer, 31 (12) ijgc-2021-003192, 1506-1507. doi: 10.1136/ijgc-2021-003192 |
|
2021 Journal Article A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020Obermair, Andreas, Nicklin, Jim, Gebski, Val, Hayes, Sandra C., Graves, Nicholas, Mileshkin, Linda, Lin, Ming Yin, Beale, Phillip, Baxter, Eva, Robledo, Kristy, Salomon, Carlos, Hanna, George B. and Janda, Monika (2021). A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020. International Journal of Gynecologic Cancer, 31 (12) ijgc-2021-003029, 1595-1601. doi: 10.1136/ijgc-2021-003029 |
|
2021 Journal Article The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancerCibula, David, Dostálek, Lukáš, Jarkovsky, Jiri, Mom, Constantijne H., Lopez, Aldo, Falconer, Henrik, Fagotti, Anna, Ayhan, Ali, Kim, Sarah H., Isla Ortiz, David, Klat, Jaroslav, Obermair, Andreas, Landoni, Fabio, Rodriguez, Juliana, Manchanda, Ranjit, Kosťun, Jan, dos Reis, Ricardo, Meydanli, Mehmet M., Odetto, Diego, Laky, Rene, Zapardiel, Ignacio, Weinberger, Vit, Benešová, Klára, Borčinová, Martina, Pari, Darwin, Salehi, Sahar, Bizzarri, Nicolò, Akilli, Huseyin, Abu-Rustum, Nadeem R. ... van Lonkhuijzen, Luc R.C.W. (2021). The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer. European Journal of Cancer, 158, 111-122. doi: 10.1016/j.ejca.2021.09.008 |
|
2021 Journal Article Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020Obermair, Andreas, Beale, Philip, Scott, Clare L, Beshay, Victoria, Kichenadasse, Ganessan, Simcock, Bryony, Nicklin, James, Lee, Yeh Chen, Cohen, Paul and Meniawy, Tarek (2021). Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. Journal of Gynecologic Oncology, 32 (6) e95, e95. doi: 10.3802/jgo.2021.32.e95 |
|
2021 Journal Article Extracellular vesicle-associated miRNAs and chemoresistance: a systematic reviewCampos, America, Sharma, Shayna, Obermair, Andreas and Salomon, Carlos (2021). Extracellular vesicle-associated miRNAs and chemoresistance: a systematic review. Cancers, 13 (18) 4608, 4608. doi: 10.3390/cancers13184608 |
|
2021 Journal Article Development of a multi-institutional prediction model for three-year survival status in patients with uterine leiomyosarcoma (AGOG11-022/QCGC1302 study)Tse, Ka-Yu, Wong, Richard Wing-Cheuk, Chao, Angel, Ueng, Shir-Hwa, Yang, Lan-Yan, Cummings, Margaret, Smith, Deborah, Lai, Chiung-Ru, Lau, Hei-Yu, Yen, Ming-Shyen, Cheung, Annie Nga-Yin, Leung, Charlotte Ka-Lun, Chan, Kit-Sheung, Chan, Alice Ngot-Htain, Li, Wai-Hon, Choi, Carmen Ka-Man, Pong, Wai-Mei, Hui, Hoi-Fong, Yuk, Judy Ying-Wah, Yao, Hung, Yuen, Nancy Wah-Fun, Obermair, Andreas, Lai, Chyong-Huey, Ip, Philip Pun-Ching and Ngan, Hextan Yuen-Sheung (2021). Development of a multi-institutional prediction model for three-year survival status in patients with uterine leiomyosarcoma (AGOG11-022/QCGC1302 study). Cancers, 13 (10) 2378, 2378. doi: 10.3390/cancers13102378 |
|
2021 Journal Article Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancerMoloney, Kristen, Janda, Monika, Frumovitz, Michael, Leitao, Mario, Abu-Rustum, Nadeem R., Rossi, Emma, Nicklin, James L., Plante, Marie, Lecuru, Fabrice R., Buda, Alessandro, Mariani, Andrea, Leung, Yee, Ferguson, Sarah Elizabeth, Pareja, Rene, Kimmig, Rainer, Tong, Pearl Shuang Ye, McNally, Orla, Chetty, Naven, Liu, Kaijiang, Jaaback, Ken, Lau, Julio, Ng, Soon Yau Joseph, Falconer, Henrik, Persson, Jan, Land, Russell, Martinelli, Fabio, Garrett, Andrea, Altman, Alon, Pendlebury, Adam ... Obermair, Andreas (2021). Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. International Journal of Gynecological Cancer, 31 (5), 647-655. doi: 10.1136/ijgc-2020-002315 |
|
2021 Journal Article Paucity of data evaluating patient centred outcomes following sentinel lymph node dissection in endometrial cancer: a systematic reviewObermair, Helena M., O'Hara, Montana, Obermair, Andreas and Janda, Monika (2021). Paucity of data evaluating patient centred outcomes following sentinel lymph node dissection in endometrial cancer: a systematic review. Gynecologic Oncology Reports, 36 100763, 100763. doi: 10.1016/j.gore.2021.100763 |
|
2021 Journal Article Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: results of a randomized clinical trialJanda, Monika, Robledo, Kristy P., Gebski, Val, Armes, Jane E., Alizart, Michelle, Brennan, Donal, Cummings, Margaret, Chen, Chen, Leung, Yee, Sykes, Peter, McNally, Orla, Oehler, Martin K., Walker, Graeme, Garrett, Andrea, Tang, Amy, Land, Russell, Nicklin, James L., Chetty, Naven, Perrin, Lewis C., Hoet, Greet, Sowden, Katherine, Eva, Lois, Tristram, Amanda and Obermair, Andreas (2021). Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: results of a randomized clinical trial. Gynecologic Oncology, 161 (1), 143-151. doi: 10.1016/j.ygyno.2021.01.029 |
|
2021 Journal Article Physical activity levels among ovarian cancer survivors: a prospective longitudinal cohort studyJones, Tamara, Sandler, Carolina, Vagenas, Dimitrios, Janda, Monika, Obermair, Andreas and Hayes, Sandra (2021). Physical activity levels among ovarian cancer survivors: a prospective longitudinal cohort study. International Journal of Gynecological Cancer, 31 (4), 553-561. doi: 10.1136/ijgc-2020-002107 |
|
2021 Journal Article Corrigendum to “Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial” [Gynecologic Oncology 161 (2021) 143–151](S0090825821000895)(10.1016/j.ygyno.2021.01.029)Janda, Monika, Robledo, Kristy P., Gebski, Val, Armes, Jane E., Alizart, Michelle, Brennan, Donal, Cummings, Margaret, Chen, Chen, Leung, Yee, Sykes, Peter, McNally, Orla, Oehler, Martin K., GraemeWalker, , Garrett, Andrea, Tang, Amy, Land, Russell, Nicklin, James L., Chetty, Naven, Perrin, Lewis C., Hoet, Greet, Sowden, Katherine, Eva, Lois, Tristram, Amanda and Obermair, Andreas (2021). Corrigendum to “Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial” [Gynecologic Oncology 161 (2021) 143–151](S0090825821000895)(10.1016/j.ygyno.2021.01.029). Gynecologic Oncology, 162 (2), 526-526. doi: 10.1016/j.ygyno.2021.05.016 |
|
2021 Journal Article Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analysesKang, Eun Young, Cheasley, Dane, LePage, Cecile, Wakefield, Matthew J., da Cunha Torres, Michelle, Rowley, Simone, Salazar, Carolina, Xing, Zhongyue, Allan, Prue, Bowtell, David D. L., Mes-Masson, Anne-Marie, Provencher, Diane M., Rahimi, Kurosh, Kelemen, Linda E., Fasching, Peter A., Doherty, Jennifer A., Goodman, Marc T., Goode, Ellen L., Deen, Suha, Pharoah, Paul D. P., Brenton, James D., Sieh, Weiva, Mateoiu, Constantina, Sundfeldt, Karin, Cook, Linda S., Le, Nhu D., Anglesio, Michael S., Gilks, C. Blake, Huntsman, David G. ... Campbell, Ian G. (2021). Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology, 34 (1), 194-206. doi: 10.1038/s41379-020-0618-9 |
